Argenx SE, Europe's largest publicly listed biotech, surged after positive clinical trial results for its blockbuster autoimmune drug Vyvgart. The rally highlights Europe's growing biotech prominence amid a strong week for the sector globally.

While Moderna Inc. captured attention with volatile price action, Argenx's gains were driven by concrete clinical progress. Vyvgart, already approved for generalized myasthenia gravis, demonstrated efficacy in additional indications, reinforcing its blockbuster potential.

Investors responded positively, pushing Argenx shares higher. The results validate the company's FcRn antagonist platform and expand Vyvgart's addressable market. Analysts note the data could support further label expansions and sustain revenue growth.

The development underscores a broader trend: European biotechs are delivering competitive late-stage assets. Argenx's success may attract more capital to the region's life sciences ecosystem, challenging US dominance in immunology innovation.